The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.

This article summarizes a discussion at LSX Biopharm America on September 11. A panel of industry experts discussed approaches to overcoming the most urgent CMC challenges during the discussion. The ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...

Produced in Partnership with ERWEKAReviewed by Emily MageeJan 6 2025 Tablets are the most common solid dosage form of medication by far, with over one trillion produced annually. 1 Tablets are mainly ...

WuXi AppTec highlighted the strength of its integrated CRDMO model and growing exposure to late-stage and commercial assets ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...